

Antibody Drug Conjugate-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A4A131CC221MEN.html>

Date: February 2018

Pages: 159

Price: US\$ 3,480.00 (Single User License)

ID: A4A131CC221MEN

Abstracts

Report Summary

Antibody Drug Conjugate-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023

Main market players of Antibody Drug Conjugate in EMEA, with company and product introduction, position in the Antibody Drug Conjugate market

Market status and development trend of Antibody Drug Conjugate by types and applications

Cost and profit status of Antibody Drug Conjugate, and marketing status

Market growth drivers and challenges

The report segments the EMEA Antibody Drug Conjugate market as:

EMEA Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Antibody Drug Conjugate Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Adcetris
Kadcyl
Other

EMEA Antibody Drug Conjugate Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Pharmaceutical Company
Research Institutions

EMEA Antibody Drug Conjugate Market: Players Segment Analysis (Company and
Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and
Gross Margin):

Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ANTIBODY DRUG CONJUGATE

- 1.1 Definition of Antibody Drug Conjugate in This Report
- 1.2 Commercial Types of Antibody Drug Conjugate
 - 1.2.1 Adcetris
 - 1.2.2 Kadcycl
 - 1.2.3 Other
- 1.3 Downstream Application of Antibody Drug Conjugate
 - 1.3.1 Hospital
 - 1.3.2 Pharmaceutical Company
 - 1.3.3 Research Institutions
- 1.4 Development History of Antibody Drug Conjugate
- 1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
 - 1.5.1 EMEA Antibody Drug Conjugate Market Status and Trend 2013-2023
 - 1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Antibody Drug Conjugate in EMEA 2013-2017
- 2.2 Consumption Market of Antibody Drug Conjugate in EMEA by Regions
 - 2.2.1 Consumption Volume of Antibody Drug Conjugate in EMEA by Regions
 - 2.2.2 Revenue of Antibody Drug Conjugate in EMEA by Regions
- 2.3 Market Analysis of Antibody Drug Conjugate in EMEA by Regions
 - 2.3.1 Market Analysis of Antibody Drug Conjugate in Europe 2013-2017
 - 2.3.2 Market Analysis of Antibody Drug Conjugate in Middle East 2013-2017
 - 2.3.3 Market Analysis of Antibody Drug Conjugate in Africa 2013-2017
- 2.4 Market Development Forecast of Antibody Drug Conjugate in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Antibody Drug Conjugate in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Antibody Drug Conjugate by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Antibody Drug Conjugate in EMEA by Types
 - 3.1.2 Revenue of Antibody Drug Conjugate in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Antibody Drug Conjugate in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Antibody Drug Conjugate in EMEA by Downstream Industry
- 4.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Africa
- 4.3 Market Forecast of Antibody Drug Conjugate in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Antibody Drug Conjugate in EMEA by Major Players
- 6.2 Revenue of Antibody Drug Conjugate in EMEA by Major Players
- 6.3 Basic Information of Antibody Drug Conjugate by Major Players
 - 6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Players
 - 6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Seattle Genetics/Takeda

7.1.1 Company profile

7.1.2 Representative Antibody Drug Conjugate Product

7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle Genetics/Takeda

7.2 Roche

7.2.1 Company profile

7.2.2 Representative Antibody Drug Conjugate Product

7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche

7.3 ImmunoGen

7.3.1 Company profile

7.3.2 Representative Antibody Drug Conjugate Product

7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen

7.4 Immunomedics

7.4.1 Company profile

7.4.2 Representative Antibody Drug Conjugate Product

7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics

7.5 Pfizer

7.5.1 Company profile

7.5.2 Representative Antibody Drug Conjugate Product

7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer

7.6 Celldex Therapeutics

7.6.1 Company profile

7.6.2 Representative Antibody Drug Conjugate Product

7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex Therapeutics

7.7 Millennium Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Antibody Drug Conjugate Product

7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals

7.8 Bayer HealthCare

7.8.1 Company profile

7.8.2 Representative Antibody Drug Conjugate Product

7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer HealthCare

7.9 Mersana Therapeutics

7.9.1 Company profile

7.9.2 Representative Antibody Drug Conjugate Product

7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana Therapeutics

7.10 Heidelberg Pharma

7.10.1 Company profile

7.10.2 Representative Antibody Drug Conjugate Product

7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Heidelberg Pharma

7.11 Oxford BioTherapeutics

7.11.1 Company profile

7.11.2 Representative Antibody Drug Conjugate Product

7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics

7.12 Takeda Pharmaceutical Company Limited

7.12.1 Company profile

7.12.2 Representative Antibody Drug Conjugate Product

7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE

8.1 Industry Chain of Antibody Drug Conjugate

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE

9.1 Cost Structure Analysis of Antibody Drug Conjugate

9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate

9.3 Labor Cost Analysis of Antibody Drug Conjugate

9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Antibody Drug Conjugate-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A4A131CC221MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4A131CC221MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970